Skip to main content
Pandorum Technologies secured 18 million dollars in Series B funding to advance its 3D bioprinting and regenerative medicine pipeline.
Funding
1 min read

Pandorum Technologies secured 18 million dollars in Series B funding to advance its 3D bioprinting and regenerative medicine pipeline.

Pandorum Technologies
Pandorum Technologies

Application

Originally reported by bharatfast.com

Pandorum Technologies secured 18 million dollars in Series B funding to advance its 3D bioprinting and regenerative medicine pipeline. This capital supports the clinical trials of Kuragenx, an FDA-designated liquid cornea therapy. For the AM industry, this signals a critical transition from lab-scale scaffolds to functional, clinical-grade tissue manufacturing. Global partnerships with AGC Biologics and Nucelion will scale this bio-fabrication infrastructure for international markets. 馃殌 #3DBioprinting #Biotech #Funding

This article is an AI-assisted rewrite of the linked source report. Facts originate from the source; phrasing is AMPulse's. Use Read Original below to verify, or Report an issue if something is wrong.

Explore Pandorum TechnologiesRead Original

How This Connects

6 related events
  1. Same pattern

    Cyfuse and NSK announce the development of a new bio-3D printer designed for the commercial production of regenerative medicine and 3D cell products.

  2. Same pattern

    Auxilium Biotechnologies is partnering with Starlab Space to deploy the AMP-1 bioprinting platform for scalable medical manufacturing in low Earth orbit.

  3. Same pattern

    PrintBio has joined a federal consortium led by WFIRM to receive up to 24.8 million USD from ARPA-H for bioprinting vascularized kidney tissue.

  4. This article

    Pandorum Technologies secured 18 million dollars in Series B funding to advance its 3D bioprinting and regenerative medicine pipeline.

  5. Same pattern

    Carnegie Mellon University secured a 28.5 million dollar ARPA-H award for the LIVE project, developing 3D-printed human liver patches.

  6. Same pattern

    Aspect Biosystems has expanded its partnership with Novo Nordisk to develop bioprinted islet therapies for Type 1 diabetes.

  7. Same pattern

    Nanochon secured $4.1M in funding to launch first-in-human trials for its 3D-printed knee implant.